-
Pharmasset Announces Two-for-One Forward Stock Split
Tuesday, August 9, 2011 - 6:52am | 98Pharmasset, Inc. (Nasdaq: VRUS) announces that its Board of Directors declared a two-for-one split of Pharmasset's common stock, par value $0.001 per share, in the form of a 100% common stock dividend. Stockholders of record as of the close of business on August 22, 2011 will receive one...
-
Phase 2 Trial of Lexicon's LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome
Tuesday, August 9, 2011 - 6:15am | 149Lexicon Pharmaceuticals (NASDAQ: LXRX) announced positive, top-line proof-of-concept data from its recently completed Phase 2 study in carcinoid syndrome with LX1032, telotristat etiprate. Carcinoid syndrome is a chronic condition caused by neuroendocrine tumors that usually originate from the...
-
Rodman & Renshaw Reiterates Market Perform on Anadys Pharmaceuticals
Tuesday, August 9, 2011 - 3:20am | 49Rodman & Renshaw reiterated its Market Perform rating on Anadys Pharmaceuticals (NASDAQ: ANDS). At the moment, the rating agency does not have a price target placed on the company's stock. On Monday, ANDS lost 9.99% of its value to finish the day at $0.72.
-
Fed Watch 08-08-2011
Monday, August 8, 2011 - 7:14pm | 979Cusick Corner All eyes will be on the Fed tomorrow, their language will be scrutinized and traders will be on edge. I got a question about what may be a signal that the equities may be potentially firming up and potentially bounce - look at commodities like Copper, JJC, Lumber, LBU11, and Cotton,...
-
Gilead Sciences to Purchase Biologics Process Research and Clinical Manufacturing Facility from Genentech
Monday, August 8, 2011 - 4:18pm | 183Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company has signed a definitive agreement under which Gilead will purchase a clinical biologics manufacturing facility and certain process development assets located in Oceanside, California from Genentech, a member of the Roche Group (...
-
NeurogesX Secures $20 Million Debt Facility
Monday, August 8, 2011 - 4:08pm | 56NeurogesX, Inc. (Nasdaq: NGSX) today announced that it has entered into a $20 million loan agreement with Hercules Technology Growth Capital, Inc. (Nasdaq: HTGC). The loan agreement includes both a $5 million accounts receivable line of credit and a $15 million term loan.
-
Array Announces New Oncology Agreement with Genentech
Monday, August 8, 2011 - 4:03pm | 133Array BioPharma (Nasdaq: ARRY) today announced an oncology agreement with Genentech, a member of the Roche Group (OTC: RHHBY), for the development of each company's small-molecule Checkpoint kinase 1 (ChK-1) program. The programs include Genentech's compound GDC-0425 (RG7602), currently in Phase 1...
-
Thanks S&P 08-08-2011
Monday, August 8, 2011 - 3:04pm | 1029Cusick's Corner Standard & Poor's has done what they said they were going to do -- downgrade the US and Government home lending agencies. After looking at the EU's efforts that will hold up Spain and Italy, it is hard to imagine that with the Fed meeting this week and the fact that our...
-
Options Brief: Cubist Pharmaceuticals
Monday, August 8, 2011 - 2:43pm | 78Shares of Cubist Pharmaceuticals (NASDAQ: CBST) are lower on the session by 7.92%, trading at $29.08. Overall put volume is now running at 8.07x the daily average, with 85% of all puts traded being purchases on the offer. 2,799 contracts have traded on the session so far. Cubist Pharmaceuticals...
-
Mr. Stephen M. Simes, President and CEO of BioSante Pharmaceuticals, Discusses the Future of LibiGel® Following Closing of $48 Million Offering
Monday, August 8, 2011 - 10:52am | 1241Point Roberts, WA, LINCOLNSHIRE, Ill - August 8, 2011 - (Investorideas.com newswire.com) Investorideas.com, an investor research portal covering leading sectors including biotech and pharma stocks, features an exclusive Q&A interview with Mr. Stephen M. Simes, President and Chief Executive...
-
NASDAQ Stocks Hitting 52-Week Lows
Monday, August 8, 2011 - 10:11am | 136Zoom Technologies Inc (NASDAQ: ZOOM) shares lost 14.49% to create a new 52-week low of $1.83. ZOOM shares have dipped 61.99% over the past 52 weeks, while the S&P 500 index has gained 6.93% in the same period. Strayer Education Inc (NASDAQ: STRA) shares fell 1.80% to touch a new 52-week low of...
-
Rodman & Renshaw Reiterates Market Outperform and PT of $5 on BioSante Pharmaceuticals
Monday, August 8, 2011 - 8:50am | 57Rodman & Renshaw reiterated its Market Outperform rating on BioSante Pharmaceuticals (NASDAQ: BPAX). At the same time, the rating agency left its price target on the company's stock unchanged at $5. On Friday, BPAX closed the day at $2.37. Its shares lost 6.33% of its value in today's pre-...
-
Bank Of America Lowers Price Target On Amylin To $15
Monday, August 8, 2011 - 8:30am | 69According to Bank of America, Amylin Pharmaceuticals (NASDAQ: AMLN) price target is lowered to $15. Bank of America said that AMLN/Takeda announced the discontinuation of their phase 2 obesity treatment candidate metreleptin/pramlintide (MP) following a pipeline review. “We assumed low probability...
-
Chelsea Therapeutics Achieves Target Enrollment in Phase II Trial of Droxidopa in Fibromyalgia
Monday, August 8, 2011 - 8:12am | 47Chelsea Therapeutics International, Ltd. (Nasdaq: CHTP) has successfully reached its target enrollment of 120 patients in its Phase II trial of droxidopa for the treatment of fibromyalgia. Top-line results of the trial are expected by the end of the year.
-
Chelsea Therapeutics Achieves Target Enrollment in Phase II Trial of Droxidopa in Fibromyalgia
Monday, August 8, 2011 - 8:07am | 141Chelsea Therapeutics International, Ltd. (Nasdaq: CHTP) has successfully reached its target enrollment of 120 patients in its Phase II trial of droxidopa for the treatment of fibromyalgia. Top-line results of the trial are expected by the end of the year. "We are delighted to have reached our...